3005-66-1Relevant academic research and scientific papers
COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS
-
Page/Page column 209, (2021/09/11)
The invention relates to a compound represented by Formula (I): or a pharmaceutically acceptable salt thereof, compositions comprising the same and methods of preparing and using the same. The variables are described herein.
Protected amino hydroxy adamantane carboxylic acid and process for its preparation
-
Paragraph 0351, (2015/11/24)
Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided. The provided compounds can be used for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.
Synthesis of 3-amlno-8-azachromans and 3-amino-7-azabenzofurans via inverse electron demand dlels-alder reaction
Badarau, Eduard,Suzenet, Franck,Finaru, Adriana-Lusninita,Guillaumet, Gerald
body text, p. 3619 - 3627 (2009/12/01)
The synthesis of 3-amino-8-azachromans and 3-amino-7-azabenzofurans derivatives is reported. The synthetic strategy is based on an inverse electron demand Diels-Alder approach, which employs 1,2,4-triazines that are judiciously substituted with amino alkynols. This approach permits the variation of the substituent on the aromatic core and on the amine moiety, as well as of the size of the nonaromatic ring.
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
-
, (2008/06/13)
Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula where x is 0 or 1 and y is 0 or 1 (provided that x=1 when y=0 and x=0 when y=1); n is 0 or 1; X is H or CN; and wherein R1, R2, R3 and R4 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.
New enantiodivergent procedure for the syntheses of chiral α- substituted serines from α-alkyl-α-aminomalonates utilizing enzymatic hydrolysis
Sano, Shigeki,Hayashi, Kazuhiko,Miwa, Toshio,Ishii, Takahiro,Fujii, Michiho,Mima, Hiromi,Nagao, Yoshimitsu
, p. 5571 - 5574 (2007/10/03)
Porcine liver esterase (PLE)- or rabbit liver esterase (RLE)-catalyzed hydrolysis of the pro-S ester group of diethyl α-alkyl-α- (benzyloxycarbonylamino)malonates 2a-c afforded (R)-ethyl α-alkyl-α- (benzyloxycarbonylamino)malonates 3a-c each in excellent enantiomeric excess. Enantiodivergent reductions of these acid esters 3a-c readily furnished both the corresponding enantiomeric α-substituted serines (R)- and (S)-5a-c.
Synthesis of Heteroaromatic Thyrotropin-releasing Hormone Analogues
Bladon, Christine M.
, p. 1151 - 1158 (2007/10/02)
Novel thyrotropin-releasing hormone (TRH) analogues containing the unnatural and heteroaromatic L-pyrrolylalanine, D-pyrrolylalanine, and L-furylalanine amino acids in position 2 have been synthesised.L-Furylalanine was obtained by the stereospecific hydrolysis of the N-acetyl-D,L-amino acid with acylase I.A protected derivative of D,L-pyrrolylalanine was prepared, the racemate was incorporated into the tripeptide and the LLL and LDL diastereoisomers were separated at the end of the synthesis.
